Figures computed from official regulatory filings — .
Ownershipinsiders 0.62% · institutions 0%
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for BIOXYTRAN, INC only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address viral infections, glycovirology, and oxygen delivery, hypoxia and degenerative diseases in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-3, a type of galectin for treatment of mild to moderate cases of Covid-19. Bioxytran, Inc. has collaboration with University of Minnesota for advance novel carbohydrate-based therapeutics. The company was founded in 2008 and is headquartered in Needham, Massachusetts.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
2 buys13 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| MILANOVA RADKA | Award | $5.1K | SEC | ||
| Other |
| n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) |
| SEC |
| CONAWAY DALE Htrack record | Award | $5.1K | SEC |
| Hoberman Alan M | Award | $5.1K | SEC |
| MILANOVA RADKA | Award | $13.5K | SEC |
| PLATT DAVIDtrack record | Other | $6.3M | Unusual size | SEC |
| CONAWAY DALE Htrack record | Award | $13.5K | SEC |
| Soderquist Ola | Other | $5.5M | Unusual size | SEC |
| Sheikh Michael | Other | $3.6M | Unusual size | SEC |
| Hoberman Alan M | Buy | $126K | conv 72First in 12mo | SEC |
| Hoberman Alan M | Award | $13.5K | SEC |
| Soderquist Ola | Other | $1K | SEC |
| Utter Anders | Award | $13.5K | SEC |
| PLATT DAVIDtrack record | Other | $4.1M | Unusual size | SEC |
| MILANOVA RADKA | Award | $31.2K | Unusual size | SEC |
| CONAWAY DALE Htrack record | Award | $31.2K | SEC |
| Hoberman Alan M | Award | $31.2K | SEC |
| Utter Anders | Award | $31.2K | SEC |
| Sheikh Michael | Other | $3.6M | Unusual size | SEC |
| Soderquist Ola | Other | $1K | SEC |
| PLATT DAVIDtrack record | Other | $4.1M | SEC |
| Soderquist Ola | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| PLATT DAVIDtrack record | Other | $6.2M | Unusual size | SEC |
| MILANOVA RADKA | Award | $9.5K | SEC |
| Soderquist Ola | Other | $5.6M | Unusual size | SEC |